Literature DB >> 12434062

Viral IL-6-induced cell proliferation and immune evasion of interferon activity.

Malini Chatterjee1, Julie Osborne, Giovanna Bestetti, Yuan Chang, Patrick S Moore.   

Abstract

Lymphoma cells infected with Kaposi's sarcoma-associated herpesvirus are autocrine dependent on virus-derived interleukin-6 (IL-6), but not on cellular IL-6. During viral infection, host cells induce the antiviral factor interferon (IFN) to up-regulate p21, initiate cell cycle arrest, and inhibit virus replication. Viral IL-6, however, blocks IFN signaling. A viral transcriptional program exists in which only the viral IL-6 gene is directly activated by IFN-alpha, allowing the virus to modify its cellular environment by sensing and responding to levels of intracellular IFN signaling. The human cytokine cannot mimic this effect because IFN-alpha down-regulates the IL-6 receptor, gp80. Viral IL-6 bypasses the gp80 regulatory checkpoint by binding directly to the gp130 transducer molecule, resulting in tumor cell autocrine dependence on the viral cytokine for proliferation and survival.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12434062     DOI: 10.1126/science.1074883

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  99 in total

Review 1.  Cytokine homologs of human gammaherpesviruses.

Authors:  Sang-Hoon Sin; Dirk P Dittmer
Journal:  J Interferon Cytokine Res       Date:  2011-12-05       Impact factor: 2.607

2.  Analysis of 4.3 kilobases of divergent locus B of macaque retroperitoneal fibromatosis-associated herpesvirus reveals a close similarity in gene sequence and genome organization to Kaposi's sarcoma-associated herpesvirus.

Authors:  Timothy M Rose; Jonathan T Ryan; Emily R Schultz; Brian W Raden; Che-Chung Tsai
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  Human herpesvirus 8-encoded cytokines.

Authors:  John Nicholas
Journal:  Future Virol       Date:  2010-03       Impact factor: 1.831

4.  An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease.

Authors:  Thomas S Uldrick; Victoria Wang; Deirdre O'Mahony; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Seth M Steinberg; Stefania Pittaluga; Irina Maric; Denise Whitby; Giovanna Tosato; Richard F Little; Robert Yarchoan
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

Review 5.  Immune evasion by Kaposi's sarcoma-associated herpesvirus.

Authors:  Hye-Ra Lee; Stacy Lee; Preet M Chaudhary; Parkash Gill; Jae U Jung
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

6.  Structural requirements for gp80 independence of human herpesvirus 8 interleukin-6 (vIL-6) and evidence for gp80 stabilization of gp130 signaling complexes induced by vIL-6.

Authors:  Daming Chen; John Nicholas
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 7.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

8.  Virus-Like Vesicles of Kaposi's Sarcoma-Associated Herpesvirus Activate Lytic Replication by Triggering Differentiation Signaling.

Authors:  Danyang Gong; Xinghong Dai; Yuchen Xiao; Yushen Du; Travis J Chapa; Jeffrey R Johnson; Xinmin Li; Nevan J Krogan; Hongyu Deng; Ting-Ting Wu; Ren Sun
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

9.  The KSHV viral interleukin-6 is not essential for latency or lytic replication in BJAB cells.

Authors:  Lei Chen; Michael Lagunoff
Journal:  Virology       Date:  2006-10-30       Impact factor: 3.616

10.  Role of protein kinase C delta in reactivation of Kaposi's sarcoma-associated herpesvirus.

Authors:  Einat Deutsch; Adina Cohen; Gila Kazimirsky; Sara Dovrat; Hadara Rubinfeld; Chaya Brodie; Ronit Sarid
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.